Anaphylaxis after first Pfizer-BioNTech COVID-19 vaccine dose rare
16 Mar 2021
byAudrey Abella
Following the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020 in the US, 21 cases of anaphylaxis have been recorded, equating to an initial estimated rate of 11.1 cases/million doses administered, according to a joint report from the US FDA and the CDC* COVID-19 Response Team.
